Literature DB >> 9710005

Campylobacter jejuni lipopolysaccharides in Guillain-Barré syndrome: molecular mimicry and host susceptibility.

K A Sheikh1, I Nachamkin, T W Ho, H J Willison, J Veitch, H Ung, M Nicholson, C Y Li, H S Wu, B Q Shen, D R Cornblath, A K Asbury, G M McKhann, J W Griffin.   

Abstract

OBJECTIVE: This study was designed to determine if the presence of specific ganglioside-like moieties in Campylobacter lipopolysaccharides (LPSs) is related to the development of Guillain-Barré syndrome (GBS), and to discover how frequently such moieties, including GM1, are present in these LPSs.
METHODS: We studied Campylobacter isolates and sera from seven patients with GBS (five acute motor axonal neuropathy, one acute inflammatory demyelinating polyneuropathy, and one Fisher's syndrome), and compared them with similar specimens from patients with Campylobacter enteritis alone.
RESULTS: All GBS patients had antiganglioside antibodies. Anti-GM1 and anti-GD1a titers were significantly elevated in post-Campylobacter GBS, both axonal and demyelinating, compared with normal control subjects or those with uncomplicated Campylobacter diarrhea. Campylobacter isolated from patients with GBS and with enteritis alone had similar ganglioside-like moieties.
CONCLUSIONS: These results indicate that patients who develop GBS respond differently to the ganglioside-like epitopes on Campylobacter than do non-GBS diarrhea patients. Our findings support a role for host susceptibility as a determinant for the outcome following Campylobacter infection. These findings have important implications for the development of vaccines against Campylobacter jejuni.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710005     DOI: 10.1212/wnl.51.2.371

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Genetic characterization of Campylobacter jejuni O:41 isolates in relation with Guillain-Barré syndrome.

Authors:  T M Wassenaar; B N Fry; A J Lastovica; J A Wagenaar; P J Coloe; B Duim
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

3.  Autoantobodies activate small GTPase RhoA to modulate neurite outgrowth.

Authors:  Kazim A Sheikh
Journal:  Small GTPases       Date:  2011-07-01

4.  Acute disseminated encephalomyelitis associated with Campylobacter jejuni infection and antiganglioside GM1 IgG antibodies.

Authors:  Carles Gaig; Francesc Valldeoriola; Albert Saiz
Journal:  J Neurol       Date:  2005-03-22       Impact factor: 4.849

Review 5.  Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases.

Authors:  Robert K Yu; Seigo Usuki; Toshio Ariga
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

Review 6.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

7.  Neurologic symptoms associated with cattle farming in the agricultural health study.

Authors:  Leora Vegosen; Meghan F Davis; Ellen Silbergeld; Patrick N Breysse; Jacqueline Agnew; Gregory Gray; Laura Beane Freeman; Freya Kamel
Journal:  J Occup Environ Med       Date:  2012-10       Impact factor: 2.162

8.  Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.

Authors:  C W Ang; M A De Klerk; H P Endtz; B C Jacobs; J D Laman; F G van der Meché; P A van Doorn
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

9.  An update on pathobiologic roles of anti-glycan antibodies in Guillain-Barré syndrome.

Authors:  Kazim A Sheikh; Gang Zhang
Journal:  F1000 Biol Rep       Date:  2010-03-25

10.  Genomic characterization of the Guillain-Barre syndrome-associated Campylobacter jejuni ICDCCJ07001 Isolate.

Authors:  Maojun Zhang; Lihua He; Qun Li; Honghe Sun; Yixin Gu; Yuanhai You; Fanliang Meng; Jianzhong Zhang
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.